...
首页> 外文期刊>Journal of Medicinal Chemistry >New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid.
【24h】

New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid.

机译:衍生自亲电性α-氨基酸氮丙啶-2,3-二羧酸的新型肽半胱氨酸蛋白酶抑制剂。

获取原文
获取原文并翻译 | 示例

摘要

Three different types of peptides containing aziridine-2, 3-dicarboxylic acid (Azi) as an electrophilic alpha-amino acid at different positions within the peptide chain (type I, N-acylated aziridines with Azi as C-terminal amino acid; type II, N-unsubstituted aziridines with Azi as N-terminal amino acid; type III, N-acylated bispeptidyl derivatives of Azi) have been synthesized and tested as inhibitors of the cysteine proteases papain, cathepsins B, L, and H, and calpains I and II, as well as against several serine proteases, one aspartate, and one metalloprotease. All aziridinyl peptides are specific cysteine protease inhibitors. Papain and cathepsins B and L are inhibited irreversibly, whereas cathepsin H and calpains are inhibited in a non-time-dependent manner. Some compounds turned out to be substrates for serine proteases and for the metalloprotease thermolysin. Remarkable differences can be observed between the three different types of inhibitors concerning stereospecificity, pH dependency of inhibition, selectivity between different cysteine proteases, and the importance of a free carboxylic acid function at the aziridine ring for inhibition. Above all type II inhibitors, aza analogues of the well-known epoxysuccinyl peptides, are potent cysteine protease inhibitors. With the exception of BOC-Leu-Gly-(S, S+R,R)-Azi-(OEt)2 (28a+b), a highly selective and potent cathepsin L inhibitor, N-acylated aziridines of type I are weaker inhibitors than type II or type III compounds. The observed results can be explained by different binding modes of the three types of inhibitors with respect to their orientation in the S- and S'-binding sites of the enzymes. Furthermore, the presence of a protonated aziridine N modifies the binding mode of type II inhibitors.
机译:三种不同类型的肽,在其肽链的不同位置上含有氮丙啶-2、3-二羧酸(Azi)作为亲电子的α-氨基酸(I型,N酰化氮丙啶,Azi作为C末端氨基酸; II型,已合成了以Azi为N末端氨基酸的N-未取代的氮丙啶; III型,Azi的N-酰化双肽基衍生物),并已作为半胱氨酸蛋白酶木瓜蛋白酶,组织蛋白酶B,L和H以及钙蛋白酶I和II,以及针对几种丝氨酸蛋白酶,一种天冬氨酸和一种金属蛋白酶。所有的氮丙啶基肽都是特定的半胱氨酸蛋白酶抑制剂。木瓜蛋白酶和组织蛋白酶B和L被不可逆地抑制,而组织蛋白酶H和钙蛋白酶以非时间依赖性方式被抑制。某些化合物被证明是丝氨酸蛋白酶和金属蛋白酶嗜热菌蛋白酶的底物。可以观察到三种不同类型的抑制剂之间的显着差异,包括立体特异性,抑制的pH依赖性,不同的半胱氨酸蛋白酶之间的选择性以及在氮丙啶环上的游离羧酸功能对于抑制的重要性。在所有II型抑制剂中,众所周知的环氧琥珀酰肽的氮杂类似物是有效的半胱氨酸蛋白酶抑制剂。除了BOC-Leu-Gly-(S,S + R,R)-Azi-(OEt)2(28a + b)(一种高选择性和有效的组织蛋白酶L抑制剂)外,I型N-酰化氮丙啶的能力较弱抑制剂比II型或III型化合物高。相对于它们在酶的S-和S'-结合位点中的取向,可以通过三种类型的抑制剂的不同结合模式来解释观察到的结果。此外,质子化氮丙啶N的存在改变了II型抑制剂的结合模式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号